Cost Effectiveness of Rasagiline and Pramipexole as Treatment Strategies in Early Parkinson's Disease in the UK Setting: An Economic Markov Model Evaluation

被引：6

作者：

Kovacs, Norbert ^{[1
]}

Janszky, Jozsef ^{[1
]}

Nagy, Ferenc ^{[1
,2
]}

机构：

[1] Univ Pecs, Dept Neurol, Pecs, Hungary

[2] Kaposi Mor Cty Hosp, Dept Neurol, Kaposvar, Hungary

来源：

DRUGS & AGING | 2011年 / 28卷 / 02期

关键词：

RANDOMIZED CONTROLLED-TRIAL; INITIAL TREATMENT; LEVODOPA;

D O I：

10.2165/80-000000000-00000

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

引用

页码：161 / 162

页数：2

共 50 条

[41] Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson's disease
Postma, Maarten J.
Boersma, Cornelis
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (01) : 1 - 4
[42] Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany
Walter, Evelyn
Odin, Per
JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (02) : 155 - 165
[43] A Markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease
Kirbach, Stephanie
Simpson, Kit
Nietert, Paul J.
Mintzer, Jacobo
CLINICAL DRUG INVESTIGATION, 2008, 28 (05) : 291 - 303
[44] A Markov Model of the Cost Effectiveness of Olanzapine Treatment for Agitation and Psychosis in Alzheimer’s Disease
Stephanie Kirbach
Kit Simpson
Paul J. Nietert
Jacobo Mintzer
Clinical Drug Investigation, 2008, 28 : 291 - 303
[45] Predictors of therapeutic benefit from treatment of Parkinson's disease with rasagiline in the real world setting
Kamudoni, Paul
Muhamed, Biju
Thomas, Chris
Raha, Sandip
Salek, Samuel
QUALITY OF LIFE RESEARCH, 2014, 23 : 93 - 93
[46] Comment to Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease
Jost, W. H.
Friede, M.
Schnitker, J.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (22) : 3349 - 3349
[47] Treatment with Rasagiline Provides Benefits in the Symptoms of Fatigue in Patients with Early Parkinson's Disease
Stocchi, F.
MOVEMENT DISORDERS, 2010, 25 : S676 - S676
[48] Indirect Comparison of Adverse Events and Dropout Rates for Early Parkinson's Disease (PD) Monotherapy Trials: Pramipexole, Ropinirole, and Rasagiline
Tarrants, M. T.
Zagmutt, F. J.
MOVEMENT DISORDERS, 2010, 25 : S724 - S725
[49] The effectiveness of pramipexole and ropinirole in early and advanced Parkinson's disease and comparision of the results with each other
Yaman, M.
Karakaya, F.
Ceviz, I.
Ozturk, S.
Kusbeci, O. Y.
MOVEMENT DISORDERS, 2013, 28 : S214 - S214
[50] COST-UTILITY ANALYSIS OF PRAMIPEXOLE EXTENDED RELEASE MONOTHERAPY IN EARLY PARKINSON'S DISEASE
Belousov, D.
Afanasieva, E.
VALUE IN HEALTH, 2015, 18 (07) : A758 - A759

← 1 2 3 4 5 →